Simulations Plus Acquires Pro-ficiency, Creating One-of-a-Kind Platform Spanning the Drug Development Continuum
Acquisition doubles the Company’s TAM to $8 billion Expected to be accretive to fiscal 2025 EPS Conference call at 5:00PM ET to discuss transaction Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations […]